Amniotic Fluid Stem Cells Prevent Development of Ascites in a Neonatal Rat Model of Necrotizing Enterocolitis

Zani, Augusto; Cananzi, Mara; Lauriti, Giuseppe; Leon, Francesco Fascetti; Wells, Jack A.; Siow, Bernard; Lythgoe, Mark F.; Pierro, Agostino; Eaton, Simon; Coppi, Paolo De

doi:10.1055/s-0033-1350059

Cited by 27 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…have shown that AF-MSCs are effective in treating experimental NEC and in reducing associated ascites via COX-2-dependent modulation of stromal cells. (3, 8) While SC were initially thought to home to and engraft into injured tissues, this is unlikely to be the case. Although engraftment occurs to some degree in various models, it is often short-lived, and the beneficial effects are more likely due to signaling mechanisms that enhance repair and modulate inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…Four SC were compared: (1) amniotic fluid-derived mesenchymal SC (AF-MSC); (2) amniotic fluid-derived neural SC (AF-NSC); (3) bone marrow-derived mesenchymal SC (BM-MSC); and (4) neonatal enteric neural SC (E-NSC). Using an established rat model of NEC, pups delivered prematurely received an intraperitoneal injection of SC.…”

Section: Methodsmentioning

confidence: 99%

“…The model of NEC was based on that described by Barlow et al . (6, 7, 20–23) Rat pups delivered via C-section one half-day prematurely were randomized into six groups: (1) breastfed ( n = 10 ); (2) NEC + 1% phosphate-buffered saline (PBS, Corning, Manassas, VA) ( n = 62 ); (3) NEC + AF-MSC ( n = 42 ); (4) NEC + AF-NSC ( n = 37 ); (5) NEC + BM-MSC ( n = 48 ); (6) NEC + E-NSC ( n = 36 ). After delivery, each pup received a single intraperitoneal (IP) injection of 2×10 6 SC in 0.1mL PBS.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Stem cells and necrotizing enterocolitis: A direct comparison of the efficacy of multiple types of stem cells

McCulloh

Olson

Zhou

et al. 2017

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Purpose Necrotizing enterocolitis (NEC) is a leading cause of gastrointestinal morbidity and mortality in premature infants. While studies have shown potential for stem cell (SC) therapy in experimental NEC, no study has compared different SC side-by-side. Our purpose was to determine whether one type of SC may more effectively treat NEC than others. Methods Four SC were compared: (1) amniotic fluid-derived mesenchymal SC (AF-MSC); (2) amniotic fluid-derived neural SC (AF-NSC); (3) bone marrow-derived mesenchymal SC (BM-MSC); and (4) neonatal enteric neural SC (E-NSC). Using an established rat model of NEC, pups delivered prematurely received an intraperitoneal injection of SC. Control pups were injected with PBS. Additional controls were breast-fed by surrogates and not subjected to experimental NEC. Intestinal tissue was graded histologically. Results NEC incidence was: PBS, 61.3%; breast-fed unstressed, 0%; AF-MSC, 19.1%; BM-MSC, 22.9%; AF-NSC, 18.9%; E-NSC 22.2%. All groups demonstrated statistical significance (p<0.05) compared to controls, and there was no difference between SC groups. Conclusion All four SC groups reduced the incidence and severity of experimental NEC equivalently. AF-MSC may be preferable due to availability of AF at delivery and ease of expansion, increasing potential for clinical translation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Stem cells and necrotizing enterocolitis: A direct comparison of the efficacy of multiple types of stem cells

McCulloh

Olson

Zhou

et al. 2017

Journal of Pediatric Surgery

View full text Add to dashboard Cite

show abstract

“…Recently, AFSCs were used in a neonatal rat model of necrotizing enterocolitis, one of the primary causes of morbidity and mortality in neonates, showed a decrease in intestinal damage, an increase in gut tissue repair and a higher survival [59,60] . A better understanding of the AFSCs biology and mechanisms of action may help to develop strategies for their use in other IBD.…”

Section: Flores Ai Et Al Stem Cell In Inflammatory Bowel Diseasementioning

confidence: 99%

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Flores¹

2015

WJSC

View full text Add to dashboard Cite

Inflammatory bowel diseases are inflammatory, chronic and progressive diseases of the intestinal tract for which no curative treatment is available. Research in other fields with stem cells of different sources and with immunoregulatory cells (regulatory T-lymphocytes and dendritic T-cells) opens up new expectations for their use in these diseases. The goal for stem cell-based therapy is to provide a permanent cure. To achieve this, it will be necessary to obtain a cellular product, original or genetically modified, that has a high migration capacity and homes into the intestine, has high survival after transplantation, regulates the immune reaction while not being visible to the patient's immune system, and repairs the injured tissue. Core tip: Inflammatory bowel diseases are inflammatory, chronic and progressive diseases of the intestinal tract. A limited experience is available with hematopoietic and mesenchymal stem cell transplantation for the treatment of these conditions. Research is ongoing with other cell lines which have been used in conditions alike to inflammatory bowel disease and which will possibly have a therapeutic role in this condition. INTRODUCTIONInflammatory bowel disease (IBD) mainly consists of two clinical conditions, Crohn's disease (CD) and ulcerative colitis (UC). It is mainly characterized by chronic, destructive inflammation of the gastrointestinal tract for which no curative treatment is currently available.Its etiology is unknown, but it is accepted that it could be the result of loss of tolerance to intraluminal bowel antigens [1] . Genetic, environmental, and microbiological factors are involved in its development, Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?Ana I Flores, Gonzalo J Gómez-Gómez, Ángeles Masedo-González, M Pilar Martínez-Montiel together with morphological and functional changes in the intestinal barrier associated to an impaired immune response [2] . Early data supporting genetic involvement in the pathogenesis of IBD come from familial clinical studies showing a greater incidence in twins [3,4] , first-degree relatives [5,6] and given ethnic groups [7,8] . Genome-wide association scan studies have allowed for identification of more than 163 loci associated to IBD [9] , 73 genes associated to CD and 47 to UC [10] , and overlapping genes for both conditions have also been found [11] . Genetic factors would however account for less than 25% of cases [12] . The exception is represented by a monogenic disorder referred to as IBD-like diseases, which are associated with severe colitis in childhood and have at most three loci alternatives [13] . On the other hand the increase of the incidence of IBD suggests that environmental factors are more important than genetic factors in the development of IBD [14] . Since IBD etiology is currently unknown, current treatment is intended to control the inflammatory intestinal process, thus avoiding irreversible structural damage. However, current therapeutic results are di...

show abstract

“…However, bone marrow MSCs proved to be ineffective in prolonging survival so they tested amniotic fluid stem cells (AFS cells). Excitingly, AFS cells significantly prolonged survival (Figure 1), improved clinical status, lowered incidence of ascites, improved macroscopic and microscopic appearance of the gut, lowered permeability and improved transit [18,46]. How are cells that are delivered intraperitoneally (i.p.)…”

Section: Effects Of Amniotic Fluid Stem Cells and Mesenchymal Stem Cementioning

confidence: 99%

Stem cells as a potential therapy for necrotizing enterocolitis

Eaton¹,

Zani

Pierro

et al. 2013

Expert Opinion on Biological Therapy

Self Cite

View full text Add to dashboard Cite

The current data are promising and demonstrate that stem cells do have an effect in rodent models of NEC. However, the short timescale, limited ability for longitudinal evaluation and uncertain clinical relevance of these models means that there are considerable challenges to be overcome before attempting stem cell therapy in clinical trials. Nevertheless, these data open up novel areas of research into a prevention or therapy for this devastating disease.

show abstract

Amniotic Fluid Stem Cells Prevent Development of Ascites in a Neonatal Rat Model of Necrotizing Enterocolitis

Cited by 27 publications

References 18 publications

Stem cells and necrotizing enterocolitis: A direct comparison of the efficacy of multiple types of stem cells

Stem cells and necrotizing enterocolitis: A direct comparison of the efficacy of multiple types of stem cells

Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Stem cells as a potential therapy for necrotizing enterocolitis

Contact Info

Product

Resources

About